You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • EP179/#734  Postoperative combined chemotherapy and radiotherapy for stage III endometrial cancer: an updated survival analysis of a multicenter retrospective study

Article Text

Article menu

Download PDFPDF

ePoster Viewing
AS04. Endometrial/Uterine corpus cancers
EP179/#734  Postoperative combined chemotherapy and radiotherapy for stage III endometrial cancer: an updated survival analysis of a multicenter retrospective study
Free
  1. Ji Geun Yoo1,
  2. Jin Hwi Kim2,
  3. Chan Joo Kim2,
  4. Hae Nam Lee3,
  5. Min Jong Song4,
  6. Dong Choon Park5,
  7. Joo Hee Yoon5,
  8. Sang Il Kim5,
  9. Soo Young Hur6 and
  10. Sung Jong Lee6
  1. 1Daejeon St. Mary’s hospital, Obstetrics and Gynecology, Daejeon, Korea, Republic of
  2. 2Catholic University of Korea Uijeongbu St Mary’s Hospital, Gynecologic Oncology, Uijeongbu City, Gyeonggi-do, Korea, Republic of
  3. 3Bucheon St. Mary’s Hospital, Obstetrics and Gynecology, Bucheon, Korea, Republic of
  4. 4Yeouido St. Mary’s Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of
  5. 5St. Vincent’s Hospital, Obstetrics and Gynecology, Suwon, Korea, Republic of
  6. 6Seoul St. Mary’s Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of

Abstract

Introduction Our previous report showed the efficacy and toxicity of adjuvant combination chemotherapy and radiation therapy (CRT) compared with chemotherapy alone (CT) in patients with stage III endometrial cancer. Here we present updated survival data with a median follow-up period of 60.0 months.

Methods Medical records of patients who received standard surgical treatment for stage III endometrial cancer at six hospitals from January 2009 to December 2019 were retrospectively reviewed. Patients who received postoperative adjuvant CRT or CT were included. Disease-free survival (DFS) and overall survival (OS) was compared using Kaplan-Meier method and log-rank test. The data cutoff date was May 1, 2013.

Results A total of 133 patients were included in the analysis, 80 (60.2%) in the CRT group and 53 (39.8%) in the CT group. In the overall population, 5-year DFS (CRT, 73% vs. CT, 65%, log-rank P = 0.290) and OS (81% vs. 75%, log-rank P = 0.400) rates were similar between treatment groups. In the subgroup of patients with stage IIIC endometrioid endometrial cancer, the CRT group had a significantly longer 5-year DFS rate compared with the CT group (76% vs. 55%, log-rank P = 0.037), but not for OS (81% vs. 71%, log-rank P = 0.450). Multivariable Cox regression analysis identified that CRT was the only independent favorable prognostic factor for DFS in this subgroup (adjusted HR, 0.43 (95% CI 0.19–0.97), P = 0.044).

Conclusion/Implications For patients with stage IIIC endometrioid endometrial cancer, CRT was associated with an improved long-germ DFS compared with CT.

Abstract EP179/#734 Figure 1
Abstract EP179/#734 Figure 1
View this table:
Abstract EP179/#734 Table 1

Factors associated with disease-free survival in FIGO stage IIIC endometrioid endometrial cancer

https://doi.org/10.1136/ijgc-2023-IGCS.266

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.